K. Glaser

发表

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.

K. Glaser, M. Staver, J. Waring, 2003, Molecular cancer therapeutics.

Histone deacetylase inhibitors: the Abbott experience.

K. Glaser, M. Curtin, 2003, Current medicinal chemistry.

Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.

K. Glaser, S. Davidsen, V. Stoll, 2005, Journal of medicinal chemistry.

Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.

K. Glaser, S. Davidsen, V. Stoll, 2007, Journal of medicinal chemistry.

Inhibition studies on the membrane-associated phospholipase A2 in vitro and prostaglandin E2 production in vivo of the macrophage-like P388D1 cell. Effects of manoalide, 7,7-dimethyl-5,8-eicosadienoic acid, and p-bromophenacyl bromide.

K. Glaser, E. Dennis, R. Ulevitch, 1989, The Journal of biological chemistry.

Manoalide: structure-activity studies and definition of the pharmacophore for phospholipase A2 inactivation.

K. Glaser, D. Faulkner, R. Jacobs, 1989, Molecular pharmacology.

Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors

Yujia Dai, K. Glaser, S. Davidsen, 2006, Molecular Cancer Therapeutics.

JAK2V617F Drives Mcl-1 Expression and Sensitizes Hematologic Cell Lines to Dual Inhibition of JAK2 and Bcl-xL

K. Glaser, Philip J. Merta, L. Roberts, 2015, PloS one.

Preclinical Characterization of ABT-348, a Kinase Inhibitor Targeting the Aurora, Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor, and Src Kinase Families

K. Glaser, S. Davidsen, C. Tse, 2012, Journal of Pharmacology and Experimental Therapeutics.

Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1.

K. Glaser, K. O’Neill, C. Hsiao, 1995, European journal of pharmacology.

Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.

K. Glaser, S. Davidsen, N. Soni, 2008, Bioorganic & medicinal chemistry letters.

Adaptation to bacterial lipopolysaccharide controls lipopolysaccharide-induced tumor necrosis factor production in rabbit macrophages.

K. Glaser, R. Ulevitch, J. Mathison, 1990, The Journal of clinical investigation.

Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors.

K. Glaser, S. Davidsen, N. Soni, 2012, Bioorganic & medicinal chemistry letters.

Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.

K. Glaser, S. Davidsen, C. Abad-Zapatero, 2011, Bioorganic & medicinal chemistry letters.

Phospholipase A2 enzymes: regulation and inhibition.

K. Glaser, D. Mobilio, J. Chang, 1993, Trends in pharmacological sciences.

Identification of VEGF Signaling Inhibition-Induced Glomerular Injury in Rats through Site-Specific Urinary Biomarkers

K. Glaser, D. Albert, E. Blomme, 2021, International journal of molecular sciences.

Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2

K. Glaser, O. Shah, L. Tucker, 2009, Cell Death and Differentiation.

1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) Induces Phosphorylation of Eukaryotic Elongation Factor-2 (eEF2)

K. Glaser, U. Warrior, Eric F. Johnson, 2011, The Journal of Biological Chemistry.

Regulation of eicosanoid biosynthesis in the macrophage. Involvement of protein tyrosine phosphorylation and modulation by selective protein tyrosine kinase inhibitors.

K. Glaser, J. Bauer, B. Weichman, 1993, Biochemical pharmacology.

Bacterial lipopolysaccharide priming of P388D1 macrophage-like cells for enhanced arachidonic acid metabolism. Platelet-activating factor receptor activation and regulation of phospholipase A2.

K. Glaser, E. Dennis, R. Asmis, 1990, The Journal of biological chemistry.

Cyclooxygenase selectivity and NSAIDs: Cyclooxygenase-2 selectivity of etodolac (LODINE)

K. Glaser, 1995, InflammoPharmacology.

Regulation of prostaglandin H synthase 2 expression in human monocytes by the marine natural products manoalide and scalaradial. Novel effects independent of inhibition of lipid mediator production.

K. Glaser, Y. Lock, 1995, Biochemical pharmacology.

Therapeutic regulation of inflammation and angiogenesis in cancer, arthritis, and asthma, sixth annual midwest meeting, Chicago, IL, USA, March 16, 1998

K. Glaser, S. Djurić, J. Winkler, 1999, Inflammation Research.

Lipopolysaccharide induces hyporesponsiveness to its own action in RAW 264.7 cells.

K. Glaser, R. Ulevitch, S. Kim, 1989, The Journal of biological chemistry.

Pharmacological characterization of the pseudopterosins: novel anti-inflammatory natural products isolated from the Caribbean soft coral, Pseudopterogorgia elisabethae.

K. Glaser, R. Jacobs, A. Mayer, 1998, Life sciences.

Strategies for the development of new antiarthritic agents.

K. Glaser, K. Molnar-Kimber, R. Sturm, 1992, International journal of immunopharmacology.

Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-α converting enzyme

K. Glaser, S. Davidsen, M. Michaelides, 2001 .

Regulation of phospholipase A2 enzymes: selective inhibitors and their pharmacological potential.

K. Glaser, 1995, Advances in pharmacology.

Inhibition of Phospholipase A2 Activation in P388D1 Macrophage-Like Cells

K. Glaser, E. Dennis, M. D. Lister, 1990 .

Macrophage phospholipase A2 activity and eicosanoid production: studies with phospholipase A2 inhibitors in P388D1 cells.

K. Glaser, E. Dennis, R. Ulevitch, 1990, Advances in experimental medicine and biology.

Inactivation of phospholipase A2 by manoalide. Localization of the manoalide binding site on bee venom phospholipase A2.

K. Glaser, T. Vedvick, R. Jacobs, 1988, Biochemical pharmacology.

Inactivation of bee venom phospholipase A2 by manoalide. A model based on the reactivity of manoalide with amino acids and peptide sequences.

K. Glaser, R. Jacobs, 1987, Biochemical pharmacology.

Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway

K. Glaser, S. Davidsen, Z. Xie, 2008, Leukemia.

Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.

K. Glaser, C. Tse, M. Michaelides, 2012, Bioorganic & medicinal chemistry letters.

Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.

K. Glaser, S. Davidsen, C. Tse, 2012, Bioorganic & medicinal chemistry letters.

Thienopyridine urea inhibitors of KDR kinase.

K. Glaser, S. Davidsen, N. Soni, 2007, Bioorganic & medicinal chemistry letters.

The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway

K. Glaser, M. Heinrich, D. Griffith, 2011, Molecular Cancer Therapeutics.

Induction of prostaglandin H synthase-2 and tumor necrosis factor-alpha in human amnionic WISH cells by various stimuli occurs through distinct intracellular mechanisms.

K. Glaser, G. Carter, K. Hulkower, 1997, The Journal of pharmacology and experimental therapeutics.

Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization

K. Glaser, S. Fesik, Mark G. Anderson, 2010, Proceedings of the National Academy of Sciences.

Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate and a secondary trypsin reaction.

K. Glaser, A. Gunasekera, P. Richardson, 2004, Analytical biochemistry.

Corrigendum to “Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate and a secondary trypsin reaction” [Anal. Biochem. 332 (2004) 90–99]

K. Glaser, A. Gunasekera, P. Richardson, 2006 .

Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.

K. Glaser, S. Davidsen, M. Michaelides, 2006, Bioorganic & medicinal chemistry letters.

Epigenetic regulation of IFN-{alpha}2b in multiple myeloma by a hydroxamic acid histone deacetylase (HDAC) inhibitor (SAHA) and a non-hydroxamic acid HDAC inhibitor (A-423378)

K. Glaser, J. Waring, E. Borden, 2007 .

Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152

K. Glaser, O. Shah, P. Tapang, 2009, The Pharmacogenomics Journal.

Sirolimus (rapamycin, Rapamune®) and combination therapy with cyclosporin A in the rat developing adjuvant arthritis model: Correlation with blood levels and the effects of different oral formulations

K. Glaser, D. Hartman, R. Carlson, 1998, Inflammation Research.

Inhibition of endotoxin-induced hypothermia and serum TNF-α levels in CD-1 mice by various pharmacological agents

K. Glaser, M. Belfast, D. Hartman, 2005, Agents and Actions.

ABT-869 a Multi-Targeted Receptor Tyrosine Kinase Inhibitor: Inhibition of FLT3 Phosphorylation and Signaling in Acute Myeloid Leukemia Running Title: ABT-869 Receptor Tyrosine Kinase Inhibitor in AML

K. Glaser, S. Davidsen, Eric F. Johnson, 2007 .

Trifluoromethyl ketones as inhibitors of histone deacetylase.

K. Glaser, S. Davidsen, M. Michaelides, 2002, Bioorganic & medicinal chemistry letters.

7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.

K. Glaser, S. Davidsen, N. Soni, 2008, Journal of medicinal chemistry.

Isoindolinone ureas: a novel class of KDR kinase inhibitors.

K. Glaser, S. Davidsen, M. Michaelides, 2004, Bioorganic & medicinal chemistry letters.

The odyssey of marine pharmaceuticals: a current pipeline perspective.

David J Newman, Robert S Jacobs, K. Glaser, 2010, Trends in pharmacological sciences.

Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).

K. Glaser, S. Davidsen, M. Michaelides, 2002, Bioorganic & medicinal chemistry letters.

3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases.

K. Glaser, S. Davidsen, N. Soni, 2008, Journal of medicinal chemistry.

Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.

Zhiqin Ji, Irini Akritopoulou-Zanze, K. Glaser, 2008, Bioorganic & medicinal chemistry letters.

Molecular pharmacology of manoalide. Inactivation of bee venom phospholipase A2.

K. Glaser, R. Jacobs, 1986, Biochemical pharmacology.

A renaissance in marine pharmacology: from preclinical curiosity to clinical reality.

K. Glaser, A. Mayer, Keith B Glaser, 2009, Biochemical pharmacology.

Luffariellolide, an anti-inflammatory sesterterpene from the marine spongeLuffariella sp.

K. Glaser, D. Faulkner, R. Jacobs, 1987, Experientia.

Discovery of Selective Hydroxamic Acid Inhibitors of Tumor Necrosis Factor-α Converting Enzyme.

K. Glaser, S. Davidsen, M. Michaelides, 2010 .

Future Directions for the Discovery of Natural Product-Derived Immunomodulating Drugs.

K. Glaser, D. Adelson, M. Spedding, 2022, Pharmacological research.

HDAC inhibitors: clinical update and mechanism-based potential.

K. Glaser, 2007, Biochemical pharmacology.

Indole amide hydroxamic acids as potent inhibitors of histone deacetylases.

Yan Guo, Jun Guo, Yujia Dai, 2003, Bioorganic & medicinal chemistry letters.

Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.

K. Glaser, S. Davidsen, C. Tse, 2011 .

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.

Yujia Dai, K. Glaser, S. Davidsen, 2007, Blood.

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.

K. Glaser, S. Davidsen, Hanry Yu, 2007, Blood.

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

K. Glaser, S. Davidsen, Eric F. Johnson, 2005, Molecular Cancer Therapeutics.

Phospholipid regulation of a cyclic AMP-specific phosphodiesterase (PDE4) from U937 cells.

K. Glaser, R. Heaslip, M. DiSanto, 1995, Cellular signalling.

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor.

Hanry Yu, Chonglei Bi, K. Glaser, 2008, Leukemia research.

Defining the role of gene regulation in resistance to HDAC inhibitors--mechanisms beyond P-glycoprotein.

K. Glaser, 2006, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Role of class I and class II histone deacetylases in carcinoma cells using siRNA.

K. Glaser, M. Staver, S. Davidsen, 2003, Biochemical and biophysical research communications.

Differential protein acetylation induced by novel histone deacetylase inhibitors.

K. Glaser, M. Staver, S. Davidsen, 2004, Biochemical and biophysical research communications.

G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.

K. Glaser, J. Waring, E. Borden, 2007, The Journal of clinical investigation.

Cyanobacterial Microcystis aeruginosa lipopolysaccharide elicits release of superoxide anion, thromboxane B₂, cytokines, chemokines, and matrix metalloproteinase-9 by rat microglia.

K. Glaser, A. Mayer, J. Berry, 2011, Toxicological sciences : an official journal of the Society of Toxicology.

Transforming growth factor beta mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase.

K. Glaser, H. Moses, G. Sheppard, 2002, Molecular cancer therapeutics.

ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft.

K. Glaser, S. Davidsen, D. Albert, 2008, Journal of hepatology.

Screening for inhibitors of histone deacetylase by incorporating a spraying method to micro-arrayed compound screening.

K. Glaser, U. Warrior, D. Burns, 2004, Combinatorial chemistry & high throughput screening.

PAF and LTB4 biosynthesis in the human neutrophil: Effects of putative inhibitors of phospholipase A2 and specific inhibitors of 5-lipoxygenase

K. Glaser, J. Chang, Y. Lock, 1991, Agents and Actions.

Regulation of eicosanoid biosynthesis in vitro and in vivo by the marine natural product manoalide: a potent inactivator of venom phospholipases.

K. Glaser, R. Jacobs, A. Mayer, 1988, The Journal of pharmacology and experimental therapeutics.

Differential response of p 53 and p 21 on HDAC inhibitor-mediated apoptosis in HCT 116 colon cancer cells in vitro and in vivo

K. Glaser, E. Hahn, M. Ocker, 2007 .

Escherichia coli lipopolysaccharide potentiation and inhibition of rat neonatal microglia superoxide anion generation: correlation with prior lactic dehydrogenase, nitric oxide, tumor necrosis factor-alpha, thromboxane B2, and metalloprotease release.

K. Glaser, A. Mayer, P. Jacobson, 1999, Shock.

Gene Expression Profiling of Multiple Histone Deacetylase ( HDAC ) Inhibitors : Defining a Common Gene Set Produced by HDAC Inhibition in T 24 and MDA Carcinoma Cell Lines

Roger G. Ulrich, Jeffrey F. Waring, K. Glaser, 2003 .

ABT-869 Inhibits the Proliferation of Ewing Sarcoma Cells and Suppresses Platelet-Derived Growth Factor Receptor β and c-KIT Signaling Pathways

K. Glaser, C. Denny, K. Sakamoto, 2010, Molecular Cancer Therapeutics.

Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.

K. Glaser, M. Malamas, J. Nelson, 1996, Journal of medicinal chemistry.

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation.

K. Glaser, L. Lam, C. Tse, 2017, Biochemical and biophysical research communications.

Alpha-keto amides as inhibitors of histone deacetylase.

K. Glaser, S. Davidsen, P. Richardson, 2003, Bioorganic & Medicinal Chemistry Letters.

Enhancement of the surface expression of tumor necrosis factor α (TNFα) but not the p55 TNFα receptor in the THP-1 monocytic cell line by matrix metalloprotease inhibitors

K. Glaser, D. Morgan, Junling Li, 1999 .

Expression and functional characterization of recombinant human HDAC1 and HDAC3.

K. Glaser, M. Staver, S. Davidsen, 2004, Life sciences.

A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units.

K. Glaser, S. Davidsen, M. Michaelides, 2003, Bioorganic & medicinal chemistry letters.

Cyanobacterial Microcystis aeruginosa lipopolysaccharide elicits release of 2 superoxide anion, thromboxane B2, cytokines, chemokines, and matrix 3

K. Glaser, A. Mayer, J. Berry, 2011 .

The Marine Pharmacology and Pharmaceuticals Pipeline in 2015

K. Glaser, D. J. Newman, Alejandro M Mayer, 2016, The FASEB Journal.

Heterocyclic ketones as inhibitors of histone deacetylase.

K. Glaser, S. Davidsen, A. Vasudevan, 2003, Bioorganic & medicinal chemistry letters.

1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) Induces Phosphorylation of Eukaryotic Elongation Factor-2 (eEF2)

K. Glaser, U. Warrior, Eric F. Johnson, 2011, The Journal of Biological Chemistry.

α-Keto amides as inhibitors of histone deacetylase

Paul L. Richardson, Zhiqin Ji, Jun Guo, 2003 .

Pharmacological targeting of signaling pathways in protein kinase C-stimulated superoxide generation in neutrophil-like HL-60 cells: effect of phorbol ester, arachidonic acid and inhibitors of kinase(s), phosphatase(s) and phospholipase A2.

K. Glaser, A. Mayer, S. Brenic, 1996, The Journal of pharmacology and experimental therapeutics.

Modulation of superoxide generation in in vivo lipopolysaccharide-primed rat alveolar macrophages by arachidonic acid and inhibitors of protein kinase C, phospholipase A2, protein serine-threonine phosphatase(s), protein tyrosine kinase(s) and phosphatase(s).

K. Glaser, R. Stocker, A. Mayer, 1995, The Journal of pharmacology and experimental therapeutics.

The Marine Pharmacology and Pharmaceuticals Pipeline in 2017

K. Glaser, D. J. Newman, Jefferson Trieu, 2018 .

The Multi-Targeted Receptor Tyrosine Kinase Inhibitor, ABT-869, Induces Apoptosis of AML Cells Both In Vitro and In Vivo.

K. Glaser, S. Davidsen, K. Sakamoto, 2005 .

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.

K. Glaser, S. Davidsen, Eric F. Johnson, 2007, Blood.